Antiva Biosciences
Clinical-stage biopharmaceutical company developing a topical intravaginal therapeutic to treat high‑risk human papillomavirus (HPV) infection and pre‑cancerous cervical lesions (CIN 2,3). The company applies prodrug medicinal chemistry and topical formulation to create a vaginal insert intended for self-administration, has advanced its lead candidate through IND‑enabling studies and Phase 1/1b/2 clinical trials, and pursues global development and access strategies for low- and middle‑income countries.
Industries
Nr. of Employees
small (1-50)
Antiva Biosciences
555 Twin Dolphin Drive, Suite 620 Redwood City, CA 94065
Patents
Compositions and dosage forms for treatment of HPV infection and HPV-induced neoplasia
US-12329768-B2
View Details
Compositions and dosage forms for treatment of HPV infection and HPV-induced neoplasia
US-12329768-B2
View DetailsProducts
ABI-2280
Investigational topical intravaginal prodrug intended to treat high‑risk HPV infection and high‑grade cervical intraepithelial neoplasia (HSIL, CIN 2,3); formulated for epithelial uptake to achieve local activity while minimizing systemic exposure.
ABI-2280
Investigational topical intravaginal prodrug intended to treat high‑risk HPV infection and high‑grade cervical intraepithelial neoplasia (HSIL, CIN 2,3); formulated for epithelial uptake to achieve local activity while minimizing systemic exposure.
Expertise Areas
- Topical antiviral drug development
- Women's health therapeutics (HPV and CIN)
- Clinical trial management (Phase 1–2 randomized studies)
- Prodrug medicinal chemistry
Key Technologies
- Acyclic nucleoside phosphonate prodrug chemistry
- Topical intravaginal insert formulation
- Intravaginal applicator / self‑administration systems
- Host DNA polymerase inhibition mechanism
News & Updates
Conference presentation reporting primary and secondary endpoint achievement and statistically significant improvements in hrHPV negativity at Weeks 12 and 24; safety and tolerability described as favorable.
Top‑line Phase 1b/2 results reporting statistically significant hrHPV negativity (46% vs 16% placebo at Week 12) and durable responses with favorable safety.
Series D financing to support continued development of ABI‑2280 and near‑term advancement into clinical trials, led by a syndicate including Adjuvant Capital and GV.
Profile of company leadership and early clinical development progress (ABI‑1968/ABI‑2280 program history).
Selected as a winner by the World Bank Group and Consumer Technology Association recognizing technology-enabled solutions to improve women’s health in emerging markets.
Series B, C, C‑1, D and E financings completed to fund clinical and product development.
Conference presentation reporting primary and secondary endpoint achievement and statistically significant improvements in hrHPV negativity at Weeks 12 and 24; safety and tolerability described as favorable.
Top‑line Phase 1b/2 results reporting statistically significant hrHPV negativity (46% vs 16% placebo at Week 12) and durable responses with favorable safety.
Series D financing to support continued development of ABI‑2280 and near‑term advancement into clinical trials, led by a syndicate including Adjuvant Capital and GV.
Profile of company leadership and early clinical development progress (ABI‑1968/ABI‑2280 program history).
Selected as a winner by the World Bank Group and Consumer Technology Association recognizing technology-enabled solutions to improve women’s health in emerging markets.
Series B, C, C‑1, D and E financings completed to fund clinical and product development.